Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market 2020 By Drug Class [Folate Antagonists, Glycopeptide Antibiotics, Lipopeptide, Oxazolidinones, Sulfa Drugs, Tetracyclines and others],By MRSA Type [Hospital-Acquired (HA-MRSA) and Community-Acquired (CA-MRSA)], By Disease Indication[Skin Infections, Bone and Joint Infections, Bacteremia and Animal Infections], By End User[Hospitals and Clinics, Research and Academic Institutes and Others]: Global Forecast to 2026 and COVID-19 Impact Outlook
Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market is valued at USD 3.66 Billion in 2019 and expected to reach USD 4.88 Billion by 2026 with the CAGR of 4.2 % over the forecast period.
Scope of the report
This report analyses the global market for Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs. The report will enable the user to understand and gain insights into the current and forecast market situation. The market is comprehensively analyzed by geography to give complete information on the global scenario. The qualitative and quantitative data provided in this study can help user understand which market segments, regions are expected to grow at higher rates, factors affecting the market and key opportunity areas. The report also includes competitive landscape of key players in the industry along with emerging trends in the market.
Key Players
Allergan, Basilea Pharmaceutica Ltd, Cellceutix, Cempra, CrystalGenomics, Debiopharm, Galapagos, GSK, Merck & Co., Inc., Pfizer, Inc., The Medicines Company, Theravance Biopharma and others
Above mentioned companies were scrutinized to assess competitive landscape of global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs market. Report provides company profiles of each player. Each profile include company product portfolio,business overview, company governance, company financials, business strategies, manufacturing locations and production facilities, company sale, recent developments and strategic collaborations & partnerships, new product launch, company segments, application diversification and company strength and weakness analysis.
Review period: (2016-2026)
Historic Period: 2016 to 2019
Forecast Period: 2020 to 2026
Base Year: 2019
Unit: USD Billion
This Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs market report provides insights on new trade regulations, import export analysis, industry value chain analysis, market size, consumption, production analysis, capacity analysis, regional and segment market share, product launches, product pipeline analysis, impact of Covid-19 on supply chain, key regions, untapped markets, patent analysis, product approvals, continuous innovations and developments in the market.
Regions
• North America: U.S., Canada and Rest of North America
• Europe: UK, France, Germany, Italy, Spain and Rest of Europe
• Asia Pacific: China, Japan, India, Australia, Southeast Asia and Rest of Asia Pacific
• Latin America: Brazil, Mexico, Argentina and Rest of Latin America
• Middle East and Africa: Gulf Countries, Israel, Africa and Rest of Middle East and Africa
Market Segmentation
• Drug Class
o Folate Antagonists
o Glycopeptide Antibiotics
o Lipopeptide
o Oxazolidinones
o Sulfa Drugs
o Tetracyclines
• MRSA Type
o Hospital-Acquired (HA-MRSA)
o Community-Acquired (CA-MRSA)
• Disease Indication
o Skin Infections
o Bone and Joint Infections
o Bacteremia
o Animal Infections
• End User
o Hospitals and Clinics
o Research and Academic Institutes
o Others
Report Coverage
• An overview of the global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs market
• In depth analysis of market dynamics and major factors such as drivers, restraints, opportunities and trends influencing the global market
• Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs market revenue data historic and forecast analysis (2016 to 2026)
• Characterization and quantification of the market segments for Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs market
• Market share analysis of key market participants and their competitive landscape
Important Questions Answered by Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Report
• What is the impact of COVID 19 epidemic on the global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs market?
• Which is mostly affected region, country?
• Which is the current largest and fastest-growing region?
• What is the market size and growth rate of the global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs market?
• What are current factors affecting the growth of market?
• What are Key trends and opportunity areas?
• Within Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs market, which segments are fastest growing & emerging strongly? What are the drivers and restraints for each segment? What are vendor competencies by segment?
• What are the major strategies adopted by leading market companies?
• What are company challenges and essential success factors by marketsegment?
• How company offerings and supply chain capabilitiesare shifting to meetemerging market needs?
Table of Contents
1. Introduction
1.1. Report Description
1.2. Market Segmentation
1.3. Research Methodology
1.4. List of Abbreviations
2. Executive Summary
3. Market Overview
3.1. Market Definition
3.2. Market Scope
3.3. Market Drivers
3.4. Market Restraints
3.5. Market Opportunities and Trends
3.6. Porter’s five force analysis
3.7. SWOT Analysis
3.8. PEST Analysis
3.9. Patent Analysis
3.10. Impact of COVID 19 on Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market
4. Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, By Drug Class, Market Size and Forecast 2016 -2026 (USD Billion)
4.1. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market By Drug Class, 2016 -2026 (USD Billion)
4.1.1. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market By Folate Antagonists
4.1.2. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market By Glycopeptide Antibiotics
4.1.3. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market By Lipopeptide
4.1.4. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market By Oxazolidinones
4.1.5. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market By Sulfa Drugs
4.1.6. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market By Tetracyclines
4.2. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market By Drug Class Share, 2016 -2026 (%)
5. Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, By Disease Indication, Market Size and Forecast 2016 -2026 (USD Billion)
5.1. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market By Disease Indication, 2016 -2026 (USD Billion)
5.1.1. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market By Skin Infections
5.1.2. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market By Bone and Joint Infections
5.1.3. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market By Bacteremia
5.1.4. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market By Animal Infections
5.2. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market By Disease Indication Share, 2016 -2026 (%)
6. Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, By MRSA Type, Market Size and Forecast 2016 -2026 (USD Billion)
6.1. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market By MRSA Type, 2016 -2026 (USD Billion)
6.1.1. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market By Hospital-Acquired (HA-MRSA)
6.1.2. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market By Community-Acquired (CA-MRSA)
6.2. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market By MRSA Type Share, 2016 -2026 (%)
7. Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, By End User, Market Size and Forecast 2016 -2026 (USD Billion)
7.1. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market By End User, 2016 -2026 (USD Billion)
7.1.1. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market By Hospitals and Clinics
7.1.2. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market By Research and Academic Institutes
7.1.3. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market By Others
7.2. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market By End User Share, 2016 -2026 (%)
8. Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, By Region Market Size and Forecast 2016 -2026
8.1. NORTH AMERICA
8.1.1. Key Findings
8.1.2. Impact of COVID 19
8.1.3. Key market trends, growth factors and opportunities
8.1.4. North America Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market by Country 2016 -2026 (USD Billion)
8.1.5. North America Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market By Drug Class 2016 -2026 (USD Billion)
8.1.6. North America Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market By MRSA Type 2016 -2026 (USD Billion)
8.1.7. North America Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market By Disease Indication 2016 -2026 (USD Billion)
8.1.8. North America Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market By End User 2016 -2026 (USD Billion)
8.2. EUROPE
8.2.1. Key Findings
8.2.2. Impact of COVID 19
8.2.3. Key market trends, growth factors and opportunities
8.2.4. Europe Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market by Country 2016 -2026 (USD Billion)
8.2.5. Europe Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market By Drug Class 2016 -2026 (USD Billion)
8.2.6. Europe Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market By MRSA Type 2016 -2026 (USD Billion)
8.2.7. Europe Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market By Disease Indication 2016 -2026 (USD Billion)
8.2.8. Europe Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market By End User 2016 -2026 (USD Billion)
8.3. ASIA PACIFIC
8.3.1. Key Findings
8.3.2. Impact of COVID 19
8.3.3. Key market trends, growth factors and opportunities
8.3.4. Asia Pacific Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market by Country 2016 -2026 (USD Billion)
8.3.5. Asia Pacific Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market By Drug Class 2016 -2026 (USD Billion)
8.3.6. Asia Pacific Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market By MRSA Type 2016 -2026 (USD Billion)
8.3.7. Asia Pacific Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market By Disease Indication 2016 -2026 (USD Billion)
8.3.8. Asia Pacific Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market By End User 2016 -2026 (USD Billion)
8.4. LATIN AMERICA
8.4.1. Key Findings
8.4.2. Impact of COVID 19
8.4.3. Key market trends, growth factors and opportunities
8.4.4. Latin America Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market by Country 2016 -2026 (USD Billion)
8.4.5. Latin America Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market By Drug Class 2016 -2026 (USD Billion)
8.4.6. Latin America Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market By MRSA Type 2016 -2026 (USD Billion)
8.4.7. Latin America Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market By Disease Indication 2016 -2026 (USD Billion)
8.4.8. Latin America Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market By End User 2016 -2026 (USD Billion)
8.5. MIDDLE EAST AND AFRICA
8.5.1. Key Findings
8.5.2. Impact of COVID 19
8.5.3. Key market trends, growth factors and opportunities
8.5.4. Middle East and Africa Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market by Country 2016 -2026 (USD Billion)
8.5.5. Middle East and Africa Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market By Drug Class 2016 -2026 (USD Billion)
8.5.6. Middle East and Africa Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market By MRSA Type 2016 -2026 (USD Billion)
8.5.7. Middle East and Africa Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market By Disease Indication 2016 -2026 (USD Billion)
8.5.8. Middle East and Africa Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market By End User 2016 -2026 (USD Billion)
9. Competitive Landscape Analysis
9.1. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Company Revenue, (USD Billion), 2016-2019
9.2. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Company Share, (%), 2016-2019
10. Company Profiles
10.1. Allergan
10.2. Basilea Pharmaceutica Ltd
10.3. Cellceutix
10.4. Cempra
10.5. CrystalGenomics
10.6. Debiopharm
10.7. Galapagos
10.8. GSK
10.9. Merck & Co., Inc.
10.10. Pfizer, Inc.
10.11. The Medicines Company
10.12. Theravance Biopharma
10.13. Others
11. Appendix
12. List of Tables
13. List of Figures
